{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:06:10Z","timestamp":1793696770860,"version":"4.5.1"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Scientific Research Deanship at the University of Ha\u2019il","award":["RG-23 121"],"award-info":[{"award-number":["RG-23 121"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s43440-025-00749-y","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T03:12:24Z","timestamp":1749784344000},"page":"889-906","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Inflammatory lung diseases: a clinical and scientific review of the latest advances and challenges"],"prefix":"10.1007","volume":"77","author":[{"given":"Ahmed A.","family":"Katamesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Almansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimaa M.","family":"Hassoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ossama M.","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Khaled Bin","family":"Break","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randa Mohammed","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obaid","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Radwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"issue":"1","key":"749_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5334\/aogh.2419","volume":"85","author":"JA Barta","year":"2019","unstructured":"Barta JA, Powell CA, Wisnivesky JP. Global epidemiology of lung Cancer. Annals Global Health. 2019;85(1):8.","journal-title":"Annals Global Health"},{"issue":"3","key":"749_CR2","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1513\/AnnalsATS.201311-405PS","volume":"11","author":"T Ferkol","year":"2014","unstructured":"Ferkol T, Schraufnagel D. The global burden of respiratory disease. Annals Am Thorac Soc. 2014;11(3):404\u20136.","journal-title":"Annals Am Thorac Soc"},{"key":"749_CR3","doi-asserted-by":"crossref","unstructured":"Zar HJ, Ferkol TW. The global burden of respiratory disease\u2014impact on child health. Wiley Online Library; 2014. pp. 430\u20134.","DOI":"10.1002\/ppul.23030"},{"key":"749_CR4","doi-asserted-by":"crossref","unstructured":"Shukla SD, Swaroop Vanka K, Chavelier A, Shastri MD, Tambuwala MM, Bakshi HA et al. Chap. 1 - Chronic respiratory diseases: An introduction and need for novel drug delivery approaches, in Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems, K. Dua, Editors. 2020, Academic Press. pp. 1\u201331.","DOI":"10.1016\/B978-0-12-820658-4.00001-7"},{"key":"749_CR5","doi-asserted-by":"crossref","unstructured":"Ramamurthy D, Nundalall T, Cingo S, Mungra N, Karaan M, Naran K et al. Recent advances in immunotherapies against infectious diseases. Immunotherapy Adv. 2020;1(1).","DOI":"10.1093\/immadv\/ltaa007"},{"key":"749_CR6","doi-asserted-by":"publisher","first-page":"1366260","DOI":"10.3389\/fimmu.2024.1366260","volume":"15","author":"Y Xiang","year":"2024","unstructured":"Xiang Y, Liu X, Wang Y, Zheng D, Meng Q, Jiang L, et al. Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges. Front Immunol. 2024;15:1366260.","journal-title":"Front Immunol"},{"issue":"6","key":"749_CR7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S2213-2600(20)30105-3","volume":"8","author":"GBDCRD Collaborators","year":"2020","unstructured":"Collaborators GBDCRD. Prevalence and attributable health burden of chronic respiratory diseases, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet Respir Med. 2020;8(6):585\u201396.","journal-title":"Lancet Respir Med"},{"key":"749_CR8","doi-asserted-by":"publisher","first-page":"101936","DOI":"10.1016\/j.eclinm.2023.101936","volume":"59","author":"GBD","year":"2023","unstructured":"GBD. Global burden of chronic respiratory diseases and risk factors, 1990\u20132019: an update from the global burden of disease study 2019. EClinicalMedicine. 2023;59:101936.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"749_CR9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12931-020-1291-8","volume":"21","author":"M Xie","year":"2020","unstructured":"Xie M, Liu X, Cao X, Guo M, Li X. Trends in prevalence and incidence of chronic respiratory diseases from 1990 to 2017. Respir Res. 2020;21(1):49.","journal-title":"Respir Res"},{"issue":"9","key":"749_CR10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-2600(17)30293-X","volume":"5","author":"JB Soriano","year":"2017","unstructured":"Soriano JB, Abajobir AA, Abate KH, Abera SF, Agrawal A, Ahmed MB, et al. Global, regional, and National deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990\u20132015: a systematic analysis for the global burden of disease study 2015. Lancet Respiratory Med. 2017;5(9):691\u2013706.","journal-title":"Lancet Respiratory Med"},{"issue":"167","key":"749_CR11","doi-asserted-by":"publisher","first-page":"220210","DOI":"10.1183\/16000617.0210-2022","volume":"32","author":"GM Joy","year":"2023","unstructured":"Joy GM, Arbiv OA, Wong CK, Lok SD, Adderley NA, Dobosz KM, et al. Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis. Eur Respiratory Rev. 2023;32(167):220210.","journal-title":"Eur Respiratory Rev"},{"issue":"5","key":"749_CR12","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1183\/09031936.00142414","volume":"45","author":"PGJ Burney","year":"2015","unstructured":"Burney PGJ, Patel J, Newson R, Minelli C, Naghavi M. Global and regional trends in COPD mortality, 1990\u20132010. Eur Respir J. 2015;45(5):1239\u201347.","journal-title":"Eur Respir J"},{"key":"749_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-031-32259-4_1","volume":"1426","author":"T Merhej","year":"2023","unstructured":"Merhej T, Zein JG. Epidemiology of asthma: prevalence and burden of disease. Adv Exp Med Biol. 2023;1426:3\u201323.","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"749_CR14","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44\u201368.","journal-title":"Am J Respir Crit Care Med"},{"key":"749_CR15","doi-asserted-by":"crossref","unstructured":"Belperio JA, Fishbein MC, Abtin F, Channick J, Balasubramanian SA. and J.P. Lynch iii, Pulmonary sarcoidosis: A comprehensive review: past to present. J Autoimmun 2023:103107.","DOI":"10.1016\/j.jaut.2023.103107"},{"issue":"1","key":"749_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccm.2023.08.007","volume":"45","author":"L Savale","year":"2024","unstructured":"Savale L, Dorfm\u00fcller P, Boucly A, Ja\u00efs X, Lacoste-Palasset T, Jevnikar M, et al. Sarcoidosis-Associated pulmonary hypertension. Clin Chest Med. 2024;45(1):185\u201397.","journal-title":"Clin Chest Med"},{"key":"749_CR17","doi-asserted-by":"publisher","first-page":"1207641","DOI":"10.3389\/fimmu.2023.1207641","volume":"14","author":"J Plichta","year":"2023","unstructured":"Plichta J, Kuna P, Panek M. Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives. Front Immunol. 2023;14:1207641.","journal-title":"Front Immunol"},{"key":"749_CR18","doi-asserted-by":"publisher","first-page":"107515","DOI":"10.1016\/j.rmed.2023.107515","volume":"222","author":"T Pitre","year":"2024","unstructured":"Pitre T, Lupas D, Ebeido I, Colak A, Modi M, Kachkovski GV, et al. Prognostic factors associated with mortality in acute exacerbations of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Respir Med. 2024;222:107515.","journal-title":"Respir Med"},{"issue":"3","key":"749_CR19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/crj.13475","volume":"16","author":"D Jiang","year":"2022","unstructured":"Jiang D, Xiao H, Dong R, Geng J, Xie B, Ren Y, et al. Krebs von Den Lungen-6 levels in untreated idiopathic pulmonary fibrosis. Clin Respir J. 2022;16(3):234\u201343.","journal-title":"Clin Respir J"},{"issue":"8","key":"749_CR20","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","volume":"201","author":"ED Crouser","year":"2020","unstructured":"Crouser ED, Maier LA, Wilson KC, Bonham CA, Morgenthau AS, Patterson KC, et al. Diagnosis and detection of sarcoidosis. An official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(8):e26\u201351.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"749_CR21","doi-asserted-by":"publisher","first-page":"e0150586","DOI":"10.1371\/journal.pone.0150586","volume":"11","author":"B Su","year":"2016","unstructured":"Su B, Liu T, Fan H, Chen F, Ding H, Wu Z, et al. Inflammatory markers and the risk of chronic obstructive pulmonary disease: A systematic review and Meta-Analysis. PLoS ONE. 2016;11(4):e0150586.","journal-title":"PLoS ONE"},{"key":"749_CR22","doi-asserted-by":"crossref","unstructured":"Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease\u2013antiprotease imbalance, and inflammation. Int J Chronic Obstr Pulm Dis, 2011: pp. 413\u201321.","DOI":"10.2147\/COPD.S10770"},{"key":"749_CR23","doi-asserted-by":"crossref","unstructured":"Wang Y, Xu J, Meng Y, Adcock IM, Yao X. Role of inflammatory cells in airway remodeling in COPD. Int J Chronic Obstr Pulm Dis, 2018: pp. 3341\u20138.","DOI":"10.2147\/COPD.S176122"},{"issue":"2","key":"749_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2169\/internalmedicine.46.1775","volume":"46","author":"S Teramoto","year":"2007","unstructured":"Teramoto S. 1. COPD pathogenesis from the viewpoint of risk factors. Intern Med. 2007;46(2):77\u201380.","journal-title":"Intern Med"},{"issue":"3","key":"749_CR25","doi-asserted-by":"publisher","first-page":"L205","DOI":"10.1152\/ajplung.00330.2013","volume":"307","author":"L Zuo","year":"2014","unstructured":"Zuo L, He F, Sergakis GG, Koozehchian MS, Stimpfl JN, Rong Y, et al. Interrelated role of cigarette smoking, oxidative stress, and immune response in COPD and corresponding treatments. Am J Physiology-Lung Cell Mol Physiol. 2014;307(3):L205\u201318.","journal-title":"Am J Physiology-Lung Cell Mol Physiol"},{"issue":"6","key":"749_CR26","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1513\/pats.201001-014AW","volume":"7","author":"AM Cantin","year":"2010","unstructured":"Cantin AM. Cellular response to cigarette smoke and oxidants. Proc Am Thorac Soc. 2010;7(6):368\u201375.","journal-title":"Proc Am Thorac Soc"},{"key":"749_CR27","first-page":"118","volume":"36","author":"MD Gans","year":"2020","unstructured":"Gans MD, Gavrilova T. Understanding the immunology of asthma: pathophysiology, biomarkers, and treatments for asthma endotypes. Paediatr Respir Rev. 2020;36:118\u201327.","journal-title":"Paediatr Respir Rev"},{"issue":"3","key":"749_CR28","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.chest.2019.10.009","volume":"157","author":"N Schoettler","year":"2020","unstructured":"Schoettler N, Strek ME. Recent advances in severe asthma: from phenotypes to personalized medicine. Chest. 2020;157(3):516\u201328.","journal-title":"Chest"},{"issue":"12","key":"749_CR29","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1080\/02770903.2023.2228911","volume":"60","author":"C Armeftis","year":"2023","unstructured":"Armeftis C, Gratziou C, Siafakas N, Katsaounou P, Pana ZD, Bakakos P. An update on asthma diagnosis. J Asthma. 2023;60(12):2104\u201310.","journal-title":"J Asthma"},{"key":"749_CR30","doi-asserted-by":"crossref","unstructured":"Zhong J, Shi G. Editorial: regulation of inflammation in chronic disease. Front Immunol. 2019:10.","DOI":"10.3389\/fimmu.2019.00737"},{"key":"749_CR31","doi-asserted-by":"crossref","unstructured":"Cao Y, Yi Y, Han C, Shi B. NF-\u03baB signaling pathway in tumor microenvironment. Front Immunol. 2024:15.","DOI":"10.3389\/fimmu.2024.1476030"},{"issue":"5","key":"749_CR32","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1183\/09031936.00128008","volume":"33","author":"PJ Barnes","year":"2009","unstructured":"Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165\u201385.","journal-title":"Eur Respir J"},{"issue":"3","key":"749_CR33","doi-asserted-by":"publisher","first-page":"370","DOI":"10.23736\/S0026-4806.22.07972-1","volume":"113","author":"F Nucera","year":"2022","unstructured":"Nucera F, Mumby S, Paudel KR, Dharwal V, A DIS, Casolaro V, et al. Role of oxidative stress in the pathogenesis of COPD. Minerva Med. 2022;113(3):370\u2013404.","journal-title":"Minerva Med"},{"issue":"6","key":"749_CR34","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1378\/chest.07-1572","volume":"132","author":"GM Turino","year":"2007","unstructured":"Turino GM. Proteases in COPD: a critical pathway to injury. Chest. 2007;132(6):1724\u20135.","journal-title":"Chest"},{"issue":"5","key":"749_CR35","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1164\/rccm.201701-0218PP","volume":"195","author":"CF Vogelmeier","year":"2017","unstructured":"Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557\u201382.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1, Supplement","key":"749_CR36","first-page":"S1","volume":"10","author":"HK Reddel","year":"2022","unstructured":"Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, et al. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. J Allergy Clin Immunology: Pract. 2022;10(1, Supplement):S1\u201318.","journal-title":"J Allergy Clin Immunology: Pract"},{"key":"749_CR37","doi-asserted-by":"crossref","unstructured":"Kumar S, Bhagat V, Sahu P, Chaube MK, Behera AK, Guizani M, et al. A novel multimodal framework for early diagnosis and classification of COPD based on CT scan images and multivariate pulmonary respiratory diseases. Computer Methods and Programs in Biomedicine. 2024;243:107911.","DOI":"10.1016\/j.cmpb.2023.107911"},{"key":"749_CR38","doi-asserted-by":"crossref","unstructured":"Frith P, Attewell R, Crockett A, Price D, Beilby J. ABS49: Splitting COPD and asthma: Validation of the differential diagnosis questionnaire (DDQ) in Australian primary care. Prim Care Respir J. 2006;15(3):198.","DOI":"10.1016\/j.pcrj.2006.04.144"},{"key":"749_CR39","doi-asserted-by":"crossref","unstructured":"Jarrah A, Awad MT, Cramer-Bour C, Soubani AO. COPD overlap conditions: clinical and therapeutic implications. Am J Med Sci. 2024.","DOI":"10.1016\/j.amjms.2024.07.023"},{"issue":"6","key":"749_CR40","doi-asserted-by":"publisher","first-page":"103582","DOI":"10.1016\/j.autrev.2024.103582","volume":"23","author":"J Guiot","year":"2024","unstructured":"Guiot J, Miedema J, Cordeiro A, De Vries-Bouwstra JK, Dimitroulas T, S\u00f8ndergaard K, et al. Practical guidance for the early recognition and follow-up of patients with connective tissue disease-related interstitial lung disease. Autoimmun Rev. 2024;23(6):103582.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"749_CR41","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1183\/09031936.04.00014304","volume":"23","author":"BR Celli","year":"2004","unstructured":"Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist AS, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper. Eur Respir J. 2004;23(6):932\u201346.","journal-title":"Eur Respir J"},{"issue":"25","key":"749_CR42","first-page":"434","volume":"120","author":"K Kahnert","year":"2023","unstructured":"Kahnert K, J\u00f6rres RA, Behr J, Welte T. The diagnosis and treatment of COPD and its comorbidities. Dtsch Arztebl Int. 2023;120(25):434\u201344.","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"749_CR43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1465-9921-7-70","volume":"7","author":"MJ Sevenoaks","year":"2006","unstructured":"Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary disease, inflammation and co-morbidity\u2013 a common inflammatory phenotype? Respir Res. 2006;7(1):70.","journal-title":"Respir Res"},{"issue":"3","key":"749_CR44","first-page":"e2024038","volume":"41","author":"\u0130 \u00d6zmen","year":"2024","unstructured":"\u00d6zmen \u0130, Y\u0131ld\u0131r\u0131m E, Karak\u0131\u015f M, \u00d6zt\u00fcrk M, Ayd\u0131n R, \u015eahal E. Are the gains from pulmonary rehabilitation the same in idiopathic pulmonary fibrosis and other interstitial lung diseases? Sarcoidosis Vasc Diffuse Lung Dis. 2024;41(3):e2024038.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"749_CR45","doi-asserted-by":"publisher","first-page":"106921","DOI":"10.1016\/j.rmed.2022.106921","volume":"200","author":"R Hughes","year":"2022","unstructured":"Hughes R, Rapsomaniki E, Janson C, Keen C, Make BJ, Burgel PR, et al. Frequent productive cough: symptom burden and future exacerbation risk among patients with asthma and\/or COPD in the NOVELTY study. Respir Med. 2022;200:106921.","journal-title":"Respir Med"},{"issue":"7","key":"749_CR46","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/crj.13515","volume":"16","author":"B Komurcuoglu","year":"2022","unstructured":"Komurcuoglu B, Susam S, Batum \u00d6, Turk MA, Salik B, Karadeniz G, et al. Correlation between chest CT severity scores and clinical and biochemical parameters of COVID-19 pneumonia. Clin Respir J. 2022;16(7):497\u2013503.","journal-title":"Clin Respir J"},{"key":"749_CR47","doi-asserted-by":"crossref","unstructured":"Wijsenbeek M, Suzuki A, Maher TM. Interstitial Lung Dis Lancet. 2022;400(10354):769\u201386.","DOI":"10.1016\/S0140-6736(22)01052-2"},{"issue":"19","key":"749_CR48","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/jama.2024.3669","volume":"331","author":"TM Maher","year":"2024","unstructured":"Maher TM. Interstitial lung disease: A review. JAMA. 2024;331(19):1655\u201365.","journal-title":"JAMA"},{"issue":"4","key":"749_CR49","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1164\/rccm.202008-3328PP","volume":"203","author":"MK Han","year":"2021","unstructured":"Han MK, Agusti A, Celli BR, Criner GJ, Halpin DM, Roche N, et al. From GOLD 0 to pre-COPD. Am J Respir Crit Care Med. 2021;203(4):414\u201323.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"749_CR50","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jamasurg.2023.3239","volume":"158","author":"SN Bonner","year":"2023","unstructured":"Bonner SN, Lagisetty K, Reddy RM, Engeda Y, Griggs JJ, Valley TS. Clinical implications of removing Race-Corrected pulmonary function tests for African American patients requiring surgery for lung Cancer. JAMA Surg. 2023;158(10):1061\u20138.","journal-title":"JAMA Surg"},{"key":"749_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/257496","volume":"2011","author":"R Rafii","year":"2011","unstructured":"Rafii R, Albertson TE, Louie S, Chan AL. Update on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease. Pulmonary Med. 2011;2011:1\u201311.","journal-title":"Pulmonary Med"},{"issue":"1","key":"749_CR52","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/01902140303759","volume":"29","author":"JC Hoyt","year":"2003","unstructured":"Hoyt JC, Robbins RA, Habib M, Springall DR, Buttery LD, Polak JM, et al. Cigarette smoke decreases inducible nitric oxide synthase in lung epithelial cells. Exp Lung Res. 2003;29(1):17\u201328.","journal-title":"Exp Lung Res"},{"key":"749_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1465-9921-7-70","volume":"7","author":"MJ Sevenoaks","year":"2006","unstructured":"Sevenoaks MJ, Stockley RA. Chronic obstructive pulmonary disease, inflammation and co-morbidity\u2013a common inflammatory phenotype? Respir Res. 2006;7:1\u20139.","journal-title":"Respir Res"},{"issue":"11","key":"749_CR54","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.healun.2022.07.017","volume":"41","author":"A Koutsokera","year":"2022","unstructured":"Koutsokera A, Sykes J, Theou O, Rockwood K, Steinack C, Derkenne M-F, et al. Frailty predicts outcomes in cystic fibrosis patients listed for lung transplantation. J Heart Lung Transplantation. 2022;41(11):1617\u201327.","journal-title":"J Heart Lung Transplantation"},{"issue":"1","key":"749_CR55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41533-023-00347-6","volume":"33","author":"JK Quint","year":"2023","unstructured":"Quint JK, Ariel A, Barnes PJ. Rational use of inhaled corticosteroids for the treatment of COPD. Npj Prim Care Respiratory Med. 2023;33(1):27.","journal-title":"Npj Prim Care Respiratory Med"},{"issue":"2","key":"749_CR56","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1001\/jamainternmed.2017.7720","volume":"178","author":"M-T Wang","year":"2018","unstructured":"Wang M-T, Liou J-T, Lin CW, Tsai C-L, Wang Y-H, Hsu Y-J, et al. Association of cardiovascular risk with inhaled Long-Acting bronchodilators in patients with chronic obstructive pulmonary disease: A nested Case-Control study. JAMA Intern Med. 2018;178(2):229\u201338.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"749_CR57","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/bjp.2008.284","volume":"155","author":"M Cazzola","year":"2008","unstructured":"Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol. 2008;155(3):291\u20139.","journal-title":"Br J Pharmacol"},{"key":"749_CR58","doi-asserted-by":"crossref","unstructured":"Radwan A, H.A.E.-A. Salem MEA, Abdelrahim AA, Farhat, Attia GA. Inhaled corticosteroids and leukotriene modifiers as mono-therapy for mild persistent asthma. Egypt J Chest Dis Tuberculosis. 2013;62(3):363\u20139.","DOI":"10.1016\/j.ejcdt.2013.06.008"},{"issue":"5","key":"749_CR59","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.nano.2015.01.007","volume":"11","author":"P Muralidharan","year":"2015","unstructured":"Muralidharan P, Malapit M, Mallory E, Hayes D Jr, Mansour HM. Inhalable nanoparticulate powders for respiratory delivery. Nanomed Nanotechnol Biol Med. 2015;11(5):1189\u201399.","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"8","key":"749_CR60","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.4155\/tde.13.67","volume":"4","author":"M Ibrahim","year":"2013","unstructured":"Ibrahim M, Garcia-Contreras L. Mechanisms of absorption and elimination of drugs administered by inhalation. Therapeutic Delivery. 2013;4(8):1027\u201345.","journal-title":"Therapeutic Delivery"},{"key":"749_CR61","doi-asserted-by":"crossref","unstructured":"Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Med Devices: Evid Res. 2015:131\u20139.","DOI":"10.2147\/MDER.S48888"},{"issue":"7","key":"749_CR62","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.arbr.2019.09.013","volume":"56","author":"JMD L\u00f3pez","year":"2020","unstructured":"L\u00f3pez JMD, Gonz\u00e1lez BG, Alc\u00e1zar-Navarrete B. Personalized medicine in chronic obstructive pulmonary disease: how close are we? Arch Bronconeumol. 2020;56(7):420\u20131.","journal-title":"Arch Bronconeumol"},{"key":"749_CR63","doi-asserted-by":"crossref","unstructured":"Antus B, Barta I. Blood eosinophils and exhaled nitric oxide: surrogate biomarkers of airway eosinophilia in stable COPD and exacerbation. Biomedicines. 2022;10(9).","DOI":"10.3390\/biomedicines10092128"},{"key":"749_CR64","doi-asserted-by":"publisher","first-page":"119969","DOI":"10.1016\/j.lfs.2021.119969","volume":"285","author":"N Gulati","year":"2021","unstructured":"Gulati N, Chellappan DK, MacLoughlin R, Dua K, Dureja H. Inhaled nano-based therapeutics for inflammatory lung diseases: recent advances and future prospects. Life Sci. 2021;285:119969.","journal-title":"Life Sci"},{"issue":"12","key":"749_CR65","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2217\/nnm-2021-0389","volume":"17","author":"M Kumar","year":"2022","unstructured":"Kumar M, Jha A, Bharti K, Parmar G, Mishra B. Advances in Lipid-Based pulmonary nanomedicine for the management of inflammatory lung disorders. Nanomedicine. 2022;17(12):913\u201334.","journal-title":"Nanomedicine"},{"key":"749_CR66","doi-asserted-by":"publisher","first-page":"108720","DOI":"10.1016\/j.cbi.2019.06.033","volume":"309","author":"P Sharma","year":"2019","unstructured":"Sharma P, Mehta M, Dhanjal DS, Kaur S, Gupta G, Singh H, et al. Emerging trends in the novel drug delivery approaches for the treatment of lung cancer. Chemico-Biol Interact. 2019;309:108720.","journal-title":"Chemico-Biol Interact"},{"key":"749_CR67","doi-asserted-by":"crossref","unstructured":"Shukla SD, Swaroop Vanka K, Chavelier A, Shastri MD, Tambuwala MM, Bakshi HA, et al. Chronic respiratory diseases: an introduction and need for novel drug delivery approaches, In Targeting chronic inflammatory lung diseases using advanced drug delivery systems. Elsevier. 2020:1\u201331.","DOI":"10.1016\/B978-0-12-820658-4.00001-7"},{"key":"749_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/2348968","volume":"2016","author":"FPR Santana","year":"2016","unstructured":"Santana FPR, Pinheiro NM, Mernak MIB, Righetti RF, Martins MA, Lago JHG, et al. Evidences of herbal Medicine-Derived natural products effects in inflammatory lung diseases. Mediat Inflamm. 2016;2016:1\u201314.","journal-title":"Mediat Inflamm"},{"key":"749_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12931-019-1065-3","volume":"20","author":"X-f Xiong","year":"2019","unstructured":"Xiong X-f, Zhu M, Wu H-x, Fan L-l, Cheng D-y. Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials. Respir Res. 2019;20:1\u201311.","journal-title":"Respir Res"},{"key":"749_CR70","doi-asserted-by":"crossref","unstructured":"Vatrella A, Fabozzi I, Calabrese C, Maselli R, Pelaia G. Dupilumab: a novel treatment for asthma. J Asthma Allergy. 2014:123\u201330.","DOI":"10.2147\/JAA.S52387"},{"issue":"5","key":"749_CR71","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.jaci.2011.04.034","volume":"128","author":"M Kumar","year":"2011","unstructured":"Kumar M, Ahmad T, Sharma A, Mabalirajan U, Kulshreshtha A, Agrawal A, et al. Let-7 microRNA\u2013mediated regulation of IL-13 and allergic airway inflammation. J Allergy Clin Immunol. 2011;128(5):1077\u201385. e10.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"749_CR72","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12865-021-00461-5","volume":"22","author":"S Uddin","year":"2021","unstructured":"Uddin S, Amour A, Lewis DJ, Edwards CD, Williamson MG, Hall S, et al. PI3K\u03b4 Inhibition prevents IL33, ILC2s and inflammatory eosinophils in persistent airway inflammation. BMC Immunol. 2021;22(1):78.","journal-title":"BMC Immunol"},{"issue":"5","key":"749_CR73","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/17425247.2021.1854222","volume":"18","author":"D Chen","year":"2021","unstructured":"Chen D, Liu J, Wu J, Suk JS. Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung. Expert Opin Drug Deliv. 2021;18(5):595\u2013606.","journal-title":"Expert Opin Drug Deliv"},{"key":"749_CR74","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1080\/00268976.2017.1351005","volume":"115","author":"P Chen","year":"2017","unstructured":"Chen P, Zhang Z, Xing J, Gu N, Ji M. Physicochemical properties of nanoparticles affect translocation across pulmonary surfactant monolayer. Mol Phys. 2017;115:3143\u201354.","journal-title":"Mol Phys"},{"issue":"23","key":"749_CR75","doi-asserted-by":"publisher","first-page":"11829","DOI":"10.1021\/acs.langmuir.4c00909","volume":"40","author":"K Tang","year":"2024","unstructured":"Tang K, Cui X. A review on investigating the interactions between nanoparticles and the pulmonary surfactant monolayer with Coarse-Grained molecular dynamics method. Langmuir. 2024;40(23):11829\u201342.","journal-title":"Langmuir"},{"key":"749_CR76","unstructured":"Cheow WS, Hadinoto K. Preparations of dry-powder therapeutic nanoparticle aerosols for inhaled drug delivery. 2010."},{"key":"749_CR77","doi-asserted-by":"crossref","unstructured":"Miller DP, Tarara TE, Weers JG. Targeting of inhaled therapeutics to the small airways: nanoleucine carrier formulations. Pharmaceutics. 2021;13(11).","DOI":"10.3390\/pharmaceutics13111855"},{"issue":"1\u20132","key":"749_CR78","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0169-409X(90)90012-H","volume":"5","author":"IW Kellaway","year":"1990","unstructured":"Kellaway IW, Farr SJ. Liposomes as drug delivery systems to the lung. Adv Drug Deliv Rev. 1990;5(1\u20132):149\u201361.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"749_CR79","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0378-5173(97)00322-0","volume":"160","author":"JC Waldrep","year":"1998","unstructured":"Waldrep JC, Arppe J, Jansa KA, Vidgren M. Experimental pulmonary delivery of cyclosporin A by liposome aerosol. Int J Pharm. 1998;160(2):239\u201349.","journal-title":"Int J Pharm"},{"key":"749_CR80","doi-asserted-by":"publisher","first-page":"101509","DOI":"10.1016\/j.jddst.2020.101509","volume":"56","author":"PP Mehta","year":"2020","unstructured":"Mehta PP, Ghoshal D, Pawar AP, Kadam SS, Dhapte-Pawar VS. Recent advances in inhalable liposomes for treatment of pulmonary diseases: concept to clinical stance. J Drug Deliv Sci Technol. 2020;56:101509.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"749_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/bbrj.bbrj_54_17","volume":"1","author":"H Suer","year":"2017","unstructured":"Suer H, Bayram H. Liposomes as potential nanocarriers for theranostic applications in chronic inflammatory lung diseases. Biomedical Biotechnol Res J (BBRJ). 2017;1(1):1.","journal-title":"Biomedical Biotechnol Res J (BBRJ)"},{"key":"749_CR82","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.2147\/IJN.S406415","volume":"18","author":"SJ Kim","year":"2023","unstructured":"Kim SJ, Puranik N, Yadav D, Jin JO, Lee PCW. Lipid Nanocarrier-Based drug delivery systems: therapeutic advances in the treatment of lung Cancer. Int J Nanomed. 2023;18:2659\u201376.","journal-title":"Int J Nanomed"},{"issue":"3","key":"749_CR83","doi-asserted-by":"publisher","first-page":"2200106","DOI":"10.1002\/anbr.202200106","volume":"3","author":"LT Ferguson","year":"2023","unstructured":"Ferguson LT, Ma X, Myerson JW, Wu J, Glassman PM, Zamora ME, et al. Mechanisms by which liposomes improve inhaled drug delivery for alveolar diseases. Adv Nanobiomed Res. 2023;3(3):2200106.","journal-title":"Adv Nanobiomed Res"},{"issue":"5","key":"749_CR84","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3109\/10611869408996819","volume":"2","author":"PN Shek","year":"1994","unstructured":"Shek PN, Suntres ZE, Brooks JI. Liposomes in pulmonary applications: physicochemical considerations, pulmonary distribution and antioxidant delivery. J Drug Target. 1994;2(5):431\u201342.","journal-title":"J Drug Target"},{"issue":"Suppl 2","key":"749_CR85","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000445116","volume":"25","author":"M Rudokas","year":"2016","unstructured":"Rudokas M, Najlah M, Alhnan MA, Elhissi A. Liposome delivery systems for inhalation: A critical review highlighting formulation issues and anticancer applications. Med Princ Pract. 2016;25(Suppl 2):60\u201372.","journal-title":"Med Princ Pract"},{"key":"749_CR86","doi-asserted-by":"crossref","unstructured":"Velino C, Carella F, Adamiano A, Sanguinetti M, Vitali A, Catalucci D et al. Nanomedicine approaches for the pulmonary treatment of cystic fibrosis. Front Bioeng Biotechnol, 2019:7.","DOI":"10.3389\/fbioe.2019.00406"},{"key":"749_CR87","doi-asserted-by":"crossref","unstructured":"Ferreira S, Domingos DDS, Ferreira TGR, Rocha R, Serakides CM, De Faria, Rezende, et al. Technetium-99m-labeled Ceftizoxime loaded long-circulating and pH-sensitive liposomes used to identify osteomyelitis. Bioorganic & Medicinal Chemistry Letters; 2012;22(14):4605\u20138.","DOI":"10.1016\/j.bmcl.2012.05.105"},{"issue":"1","key":"749_CR88","doi-asserted-by":"publisher","first-page":"117","DOI":"10.7314\/APJCP.2016.17.1.117","volume":"17","author":"N Shaban","year":"2016","unstructured":"Shaban N, Abdel-Rahman S, Haggag A, Awad D, Bassiouny A, Talaat I. Combination between Taxol-Encapsulated liposomes and Eruca sativa seed extract suppresses mammary tumors in female rats induced by 7,12 Dimethylbenz(\u03b1)anthracene. Asian Pac J Cancer Prev. 2016;17(1):117\u201323.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"749_CR89","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.pmatsci.2011.08.003","volume":"57","author":"JN Tiwari","year":"2012","unstructured":"Tiwari JN, Tiwari RN, Kim KS. Zero-dimensional, one-dimensional, two-dimensional and three-dimensional nanostructured materials for advanced electrochemical energy devices. Prog Mater Sci. 2012;57(4):724\u2013803.","journal-title":"Prog Mater Sci"},{"issue":"10183","key":"749_CR90","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819\u201330.","journal-title":"Lancet"},{"issue":"4\u20135","key":"749_CR91","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v19.i45.40","volume":"19","author":"HM Courrier","year":"2002","unstructured":"Courrier HM, Butz N, Vandamme TF. Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carr Syst. 2002;19(4\u20135):425\u201398.","journal-title":"Crit Rev Ther Drug Carr Syst"},{"issue":"1\u20132","key":"749_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.03.017","volume":"392","author":"G Pilcer","year":"2010","unstructured":"Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010;392(1\u20132):1\u201319.","journal-title":"Int J Pharm"},{"key":"749_CR93","doi-asserted-by":"crossref","unstructured":"Satapathy MK, Yen TL, Jan JS, Tang RD, Wang JY, Taliyan R et al. Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB. Pharmaceutics, 2021;13(8).","DOI":"10.3390\/pharmaceutics13081183"},{"key":"749_CR94","doi-asserted-by":"crossref","unstructured":"More D, Wadhokar SAS, Bedjawalge RS. A review on solid lipid nanoparticles as nano drug delivery transporters. Current Nanoscience. 2023.","DOI":"10.2174\/1573413719666230605120659"},{"key":"749_CR95","unstructured":"Ramadon D. Solid lipid nanoparticles (SLN): formulation and fabrication. Pharmaceutical Sciences and Research. 2023."},{"key":"749_CR96","doi-asserted-by":"crossref","unstructured":"Queiroz MdCV, Muehlmann LA. Characteristics and Preparation of solid lipid nanoparticles and nanostructured lipid carriers. J Nanotheranost. 2024.","DOI":"10.3390\/jnt5040012"},{"key":"749_CR97","doi-asserted-by":"crossref","unstructured":"Madkhali OA. Perspectives and prospective on solid lipid nanoparticles as drug delivery systems. Molecules, 2022. 27(5).","DOI":"10.3390\/molecules27051543"},{"key":"749_CR98","doi-asserted-by":"crossref","unstructured":"Qushawy MK, Nasr AM. Solid lipid nanoparticles (SLNs) as nano drug delivery carriers: preparation, characterization and application. Int J Appl Pharm. 2019.","DOI":"10.22159\/ijap.2020v12i1.35312"},{"key":"749_CR99","unstructured":"Goudanavar BSAPS. and N. Raghavendra. A comprehensive review of solid lipid nanoparticles. International Journal For Multidisciplinary Research. 2025."},{"key":"749_CR100","doi-asserted-by":"crossref","unstructured":"Sivadasan D, Ramakrishnan K, Mahendran J, Ranganathan H, Karuppaiah A, Rahman H. Solid lipid nanoparticles: applications and prospects in Cancer treatment. Int J Mol Sci. 2023;24(7).","DOI":"10.3390\/ijms24076199"},{"key":"749_CR101","doi-asserted-by":"crossref","unstructured":"Duong VA, Nguyen TT, Maeng HJ. Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of Preparation parameters of solvent injection method. Molecules, 2020. 25(20).","DOI":"10.3390\/molecules25204781"},{"issue":"1","key":"749_CR102","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s13346-023-01398-5","volume":"14","author":"E Weaver","year":"2024","unstructured":"Weaver E, Sommonte F, Hooker A, Denora N, Uddin S, Lamprou DA. Microfluidic encapsulation of enzymes and steroids within solid lipid nanoparticles. Drug Deliv Transl Res. 2024;14(1):266\u201379.","journal-title":"Drug Deliv Transl Res"},{"key":"749_CR103","doi-asserted-by":"crossref","unstructured":"Musielak E, Feliczak-Guzik A, Nowak I. Optimization of the conditions of solid lipid nanoparticles (SLN) synthesis. Molecules, 2022;27(7).","DOI":"10.3390\/molecules27072202"},{"issue":"2","key":"749_CR104","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejpb.2010.02.014","volume":"75","author":"M Nassimi","year":"2010","unstructured":"Nassimi M, Schleh C, Lauenstein HD, Hussein R, Hoymann HG, Koch W, et al. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur J Pharm Biopharm. 2010;75(2):107\u201316.","journal-title":"Eur J Pharm Biopharm"},{"issue":"7","key":"749_CR105","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1021\/acs.molpharmaceut.4c00128","volume":"21","author":"S Alwani","year":"2024","unstructured":"Alwani S, Wasan EK, Badea I. Solid lipid nanoparticles for pulmonary delivery of biopharmaceuticals: A review of opportunities, challenges, and delivery applications. Mol Pharm. 2024;21(7):3084\u2013102.","journal-title":"Mol Pharm"},{"key":"749_CR106","doi-asserted-by":"crossref","unstructured":"Bakhtiary Z, Barar J, Aghanejad A, Saei AA, Nemati E, Ezzati Nazhad J, Dolatabadi, et al. Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer. Drug Dev Ind Pharm. 2017;43(8):1244\u201353.","DOI":"10.1080\/03639045.2017.1310223"},{"key":"749_CR107","doi-asserted-by":"crossref","unstructured":"Desfran\u00e7ois C, Auz\u00e9ly R, Texier I. Lipid nanoparticles and their hydrogel composites for drug delivery: A review. Pharmaceuticals (Basel), 2018;11(4).","DOI":"10.3390\/ph11040118"},{"issue":"17","key":"749_CR108","doi-asserted-by":"publisher","first-page":"16539","DOI":"10.1021\/acsnano.3c01814","volume":"17","author":"Q Fei","year":"2023","unstructured":"Fei Q, Shalosky EM, Barnes R, Shukla VC, Xu S, Ballinger MN, et al. Macrophage-targeted lipid nanoparticle delivery of microRNA-146a to mitigate hemorrhagic shock-induced acute respiratory distress syndrome. ACS Nano. 2023;17(17):16539\u201352.","journal-title":"ACS Nano"},{"key":"749_CR109","doi-asserted-by":"crossref","unstructured":"Fei Q, Shalosky EM, Barnes R, Shukla VC, Ballinger MN, Farkas L et al. Macrophage-targeted lipid nanoparticle delivery of microRNA-146a to mitigate hemorrhagic shock-induced acute respiratory distress syndrome. BioRxiv. 2023.","DOI":"10.1101\/2023.02.17.529007"},{"issue":"1","key":"749_CR110","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41467-020-20449-w","volume":"12","author":"CM Bobba","year":"2021","unstructured":"Bobba CM, Fei Q, Shukla V, Lee H, Patel P, Putman RK, et al. Nanoparticle delivery of microRNA-146a regulates mechanotransduction in lung macrophages and mitigates injury during mechanical ventilation. Nat Commun. 2021;12(1):289.","journal-title":"Nat Commun"},{"issue":"23","key":"749_CR111","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.3748\/wjg.v23.i23.4200","volume":"23","author":"C Dianzani","year":"2017","unstructured":"Dianzani C, Foglietta F, Ferrara B, Rosa AC, Muntoni E, Gasco P, et al. Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: effects in an in vivo model. World J Gastroenterol. 2017;23(23):4200.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"749_CR112","doi-asserted-by":"publisher","first-page":"224","DOI":"10.22543\/7674.62.P224231","volume":"6","author":"TG Alexescu","year":"2019","unstructured":"Alexescu TG, Tarmure S, Negrean V, Cosnarovici M, Ruta VM, Popovici I, et al. Nanoparticles in the treatment of chronic lung diseases. J Mind Med Sci. 2019;6(2):224\u201331.","journal-title":"J Mind Med Sci"},{"issue":"11","key":"749_CR113","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.1021\/acs.molpharmaceut.9b00629","volume":"16","author":"HL O\u2019Mary","year":"2019","unstructured":"O\u2019Mary HL, Hanafy MS, Aldayel AM, Valdes SA, Alzhrani RF, Hufnagel S, et al. Effect of the ratio of betamethasone to TNF-\u03b1 SiRNA coencapsulated in solid lipid nanoparticles on the acute Proinflammatory activity of the nanoparticles. Mol Pharm. 2019;16(11):4496\u2013506.","journal-title":"Mol Pharm"},{"issue":"2","key":"749_CR114","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/pharmaceutics13020291","volume":"13","author":"M Bhia","year":"2021","unstructured":"Bhia M, Motallebi M, Abadi B, Zarepour A, Pereira-Silva M, Saremnejad F, et al. Naringenin nano-delivery systems and their therapeutic applications. Pharmaceutics. 2021;13(2):291.","journal-title":"Pharmaceutics"},{"issue":"6","key":"749_CR115","first-page":"1934578X1985846","volume":"14","author":"DT Thao","year":"2019","unstructured":"Thao DT, Nga NT, Van NA, Hung KD. Potential anticancer activities of a combination of curcumin, ginger oleoresin, and Rutin solid lipid nanoparticles (Vietlife-Antican) in LLC tumor-bearing mice. Nat Prod Commun. 2019;14(6):1934578X19858461.","journal-title":"Nat Prod Commun"},{"key":"749_CR116","unstructured":"Narain L. Recent approaches in microspheres: A novel drug delivery system. 2009."},{"issue":"5","key":"749_CR117","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3109\/03639045.2015.1075032","volume":"42","author":"G Kasten","year":"2016","unstructured":"Kasten G, Silva LF, Lemos-Senna E. Development of low density azithromycin-loaded Polycaprolactone microparticles for pulmonary delivery. Drug Dev Ind Pharm. 2016;42(5):776\u201387.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"749_CR118","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1208\/s12249-018-1215-9","volume":"20","author":"TL Terry","year":"2019","unstructured":"Terry TL, Givens BE, Rodgers VGJ, Salem AK. Tunable properties of Poly-DL-Lactide-Monomethoxypolyethylene glycol porous microparticles for sustained release of Polyethylenimine-DNA polyplexes. AAPS PharmSciTech. 2019;20(1):23.","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"749_CR119","doi-asserted-by":"publisher","first-page":"e60989","DOI":"10.1371\/journal.pone.0060989","volume":"8","author":"P Pacheco","year":"2013","unstructured":"Pacheco P, White D, Sulchek T. Effects of microparticle size and Fc density on macrophage phagocytosis. PLoS ONE. 2013;8(4):e60989.","journal-title":"PLoS ONE"},{"issue":"28","key":"749_CR120","doi-asserted-by":"publisher","first-page":"8752","DOI":"10.1021\/acs.nanolett.4c02318","volume":"24","author":"MY Liu","year":"2024","unstructured":"Liu MY, Liu X, Wang CY, Wan QQ, Tian YF, Liu SL, et al. Inhalable polymeric microparticles for phage and photothermal synergistic therapy of Methicillin-Resistant Staphylococcus aureus pneumonia. Nano Lett. 2024;24(28):8752\u201362.","journal-title":"Nano Lett"},{"key":"749_CR121","unstructured":"Mohd Rawi AF, Jaapar K, Siew Shee L, Mohamed NAH. Review of materials for the fabrication of microparticles in the context of bone tissue engineering. Compendium of Oral Science. 2024."},{"key":"749_CR122","doi-asserted-by":"crossref","unstructured":"Gangadi JR, Kokkula PK, Kannadasan M. Polymeric innovations in drug delivery: enhancing therapeutic efficacy. Int J Pharm Chem Anal. 2024.","DOI":"10.18231\/j.ijpca.2024.041"},{"issue":"4","key":"749_CR123","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1208\/s12249-018-1002-7","volume":"19","author":"RV Ubale","year":"2018","unstructured":"Ubale RV, Shastri PN, Oettinger C, D\u2019Souza MJ. Pulmonary administration of microparticulate antisense oligonucleotide (ASO) for the treatment of lung inflammation. AAPS PharmSciTech. 2018;19(4):1908\u201319.","journal-title":"AAPS PharmSciTech"},{"issue":"22","key":"749_CR124","doi-asserted-by":"publisher","first-page":"e2300226","DOI":"10.1002\/adhm.202300226","volume":"12","author":"S Jung","year":"2023","unstructured":"Jung S, Heo S, Oh Y, Park K, Park S, Choi W, et al. Zwitterionic inhaler with synergistic therapeutics for reprogramming of M2 macrophage to Pro-Inflammatory phenotype. Adv Healthc Mater. 2023;12(22):e2300226.","journal-title":"Adv Healthc Mater"},{"issue":"10","key":"749_CR125","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.2174\/0115672018265571231011093546","volume":"21","author":"KR Chaudhary","year":"2024","unstructured":"Chaudhary KR, Singh K, Singh C. Recent updates in inhalable drug delivery system against various pulmonary diseases: challenges and future perspectives. Curr Drug Deliv. 2024;21(10):1320\u201345.","journal-title":"Curr Drug Deliv"},{"issue":"18","key":"749_CR126","doi-asserted-by":"publisher","first-page":"e2309748","DOI":"10.1002\/advs.202309748","volume":"11","author":"Q Wang","year":"2024","unstructured":"Wang Q, Bu C, Dai Q, Chen J, Zhang R, Zheng X, et al. Recent progress in nucleic acid pulmonary delivery toward overcoming physiological barriers and improving transfection efficiency. Adv Sci (Weinh). 2024;11(18):e2309748.","journal-title":"Adv Sci (Weinh)"},{"issue":"2","key":"749_CR127","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3390\/ph16020158","volume":"16","author":"MR Islam","year":"2023","unstructured":"Islam MR, Feng Y. Achieving targeted delivery of chemotherapeutic particles to small airway tumors via pulmonary route using endotracheal catheters: A CFPD study. Pharmaceuticals. 2023;16(2):158.","journal-title":"Pharmaceuticals"},{"key":"749_CR128","doi-asserted-by":"crossref","unstructured":"Ma Y, He X, Liu X, Long Y, Chen Y. Endothelial microparticles derived from primary pulmonary microvascular endothelial cells mediate lung inflammation in chronic obstructive pulmonary disease by transferring microRNA-126. J Inflamm Res. 2022:1399\u2013411.","DOI":"10.2147\/JIR.S349818"},{"issue":"5","key":"749_CR129","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/SHK.0000000000000780","volume":"47","author":"AL Chang","year":"2017","unstructured":"Chang AL, Kim Y, Seitz AP, Schuster RM, Lentsch AB, Pritts TA. Erythrocyte-derived microparticles activate pulmonary endothelial cells in a murine model of transfusion. Shock. 2017;47(5):632\u20137.","journal-title":"Shock"},{"key":"749_CR130","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ejpb.2020.11.024","volume":"158","author":"T Fischer","year":"2021","unstructured":"Fischer T, Tschernig T, Drews F, Brix K, Meier C, Simon M, et al. SiRNA delivery to macrophages using aspherical, nanostructured microparticles as delivery system for pulmonary administration. Eur J Pharm Biopharm. 2021;158:284\u201393.","journal-title":"Eur J Pharm Biopharm"},{"key":"749_CR131","first-page":"3637","volume":"7","author":"E Miele","year":"2012","unstructured":"Miele E, Spinelli GP, Miele E, Di Fabrizio E, Ferretti E, Tomao S, et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomed. 2012;7:3637\u201357.","journal-title":"Int J Nanomed"},{"issue":"4","key":"749_CR132","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3390\/medicines5040133","volume":"5","author":"PJ McKiernan","year":"2018","unstructured":"McKiernan PJ, Lynch P, Ramsey JM, Cryan SA, Greene CM. Knockdown of gene expression in macrophages by MicroRNA mimic-containing Poly (lactic-co-glycolic acid) microparticles. Medicines. 2018;5(4):133.","journal-title":"Medicines"},{"issue":"1","key":"749_CR133","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1517\/17425247.2013.747507","volume":"10","author":"H Mok","year":"2013","unstructured":"Mok H, Zhang M. Superparamagnetic iron oxide nanoparticle-based delivery systems for biotherapeutics. Expert Opin Drug Deliv. 2013;10(1):73\u201387.","journal-title":"Expert Opin Drug Deliv"},{"issue":"15","key":"749_CR134","doi-asserted-by":"publisher","first-page":"1800124","DOI":"10.1002\/adhm.201800124","volume":"7","author":"MS Miranda","year":"2018","unstructured":"Miranda MS, Rodrigues MT, Domingues RMA, Costa RR, Paz E, Rodr\u00edguez-Abreu C, et al. Development of inhalable superparamagnetic Iron oxide nanoparticles (SPIONs) in microparticulate system for antituberculosis drug delivery. Adv Healthc Mater. 2018;7(15):1800124.","journal-title":"Adv Healthc Mater"},{"issue":"15","key":"749_CR135","doi-asserted-by":"publisher","first-page":"1800124","DOI":"10.1002\/adhm.201800124","volume":"7","author":"MS Miranda","year":"2018","unstructured":"Miranda MS, Rodrigues MT, Domingues RM, Costa RR, Paz E, Rodr\u00edguez-Abreu C, et al. Development of inhalable superparamagnetic iron oxide nanoparticles (SPIONs) in microparticulate system for antituberculosis drug delivery. Adv Healthc Mater. 2018;7(15):1800124.","journal-title":"Adv Healthc Mater"},{"issue":"3","key":"749_CR136","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.25258\/ijddt.13.3.44","volume":"13","author":"M Deliaz","year":"2023","unstructured":"Deliaz M, Hendradi E, Hariyadi D. Polymeric fluoroquinolone microparticles for pulmonary drug delivery: A review on characteristics, drug release profile, and antibacterial study. Int J Drug Delivery Technol. 2023;13(3):1037\u201345.","journal-title":"Int J Drug Delivery Technol"},{"issue":"1","key":"749_CR137","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1039\/C5ME00004A","volume":"1","author":"P Muralidharan","year":"2016","unstructured":"Muralidharan P, Hayes D, Black SM, Mansour HM. Microparticulate\/nanoparticulate powders of a novel Nrf2 activator and an aerosol performance enhancer for pulmonary delivery targeting the lung Nrf2\/Keap-1 pathway. Mol Syst Des Eng. 2016;1(1):48\u201365.","journal-title":"Mol Syst Des Eng"},{"issue":"4","key":"749_CR138","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11882-022-01030-5","volume":"22","author":"YK Persaud","year":"2022","unstructured":"Persaud YK. Using telemedicine to care for the asthma patient. Curr Allergy Asthma Rep. 2022;22(4):43\u201352.","journal-title":"Curr Allergy Asthma Rep"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00749-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00749-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00749-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:14:10Z","timestamp":1757189650000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00749-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":138,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["749"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00749-y","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No human or animal studies have been performed in the work toward the completion of this article. Therefore, no ethical approvals are required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}